Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
Demodex Blepharitis
Interventions
DRUG

Lotilaner ophthalmic solution, 0.25%

XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days

DRUG

Vehicle control

Vehicle of XDEMVY administered topically twice a day for approximately 43 days

Trial Locations (14)

16066

Site, Cranberry Township

28150

Site, Shelby

33484

Site, Delray Beach

38104

Site, Memphis

40206

Site, Louisville

43065

Site, Powell

46240

Site, Indianapolis

55436

Site, Edina

58103

Site, Fargo

66762

Site, Pittsburg

77005

Site, Houston

80907

Vision Institute, Colorado Springs

85331

Site, Cave Creek

90805

Site, Long Beach

All Listed Sponsors
lead

Tarsus Pharmaceuticals, Inc.

INDUSTRY

NCT06182358 - Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers | Biotech Hunter | Biotech Hunter